BANGKOK, Thailand — Thailand is making a decisive play to lead Southeast Asia’s rapidly expanding biopharmaceutical sector, opening the doors of its 80 million USD National Biopharmaceutical Facility (NBF) to an international media delegation ahead of the upcoming CPHI SouthEast Asia 2026 exhibition. Located at King Mongkut’s University of Technology Thonburi (KMUTT) Bangkhuntien Campus, the facility represents the nation’s first state-owned Contract Development and Manufacturing Organization (CDMO) dedicated to producing clinical and research-grade biologics.
The strategic push comes as the regional biopharmaceutical market undergoes a massive growth spurt. Fresh market analysis from the IMARC Group (Report ID: SR112026A21764) reveals that the Southeast Asian market was valued at 6.7 billion USD in 2025 and is on track to nearly double to 12.8 billion USD by 2034. This surge is being propelled by an aging population, a rise in chronic illnesses, advancing biotechnology, and supportive government frameworks across the ASEAN block.
Dr. Annop Nopharatana, Vice President of King Mongkut’s University of Technology Thonburi, emphasized the broader vision behind the site:
“The National Biopharmaceutical Facility is more than a research center. It is a strategic national infrastructure that bridges scientific research with industrial application, strengthening Thailand’s healthcare security, enhancing national competitiveness, and supporting the sustainable growth of the country’s biopharmaceutical industry.”
Organized by Informa Markets (Thailand), the media tour highlighted how the facility links laboratory research directly with large-scale industrial deployment. By localizing advanced production, Thailand aims to reduce its reliance on imported biologics, safeguard national vaccine supplies, and serve as an integrated biotechnology hub for neighboring countries.
During the briefing, Dr. Warinthorn Songkasiri, Vice President for Research Strategy at KMUTT and Acting Director of the NBF, outlined the operational blueprint driving this ecosystem. She noted that the facility’s mission focuses on developing scientific talent, technical workforces, and industrial partnerships that connect academic institutions, hospitals, private enterprises, and government agencies across Southeast Asia.
The NBF achieves this end-to-end pipeline through three specialized Centers of Excellence:
-
Bioprocess Research and Innovation Center (BRIC): Focuses on process design, optimization, and scaling up manufacturing. It provides GMP-compliant cell banking and technology transfers to help researchers move laboratory discoveries into viable manufacturing setups.
-
Biopharmaceutical Characterization Laboratory (BPCL): Operating under ISO/IEC 17025 certification, this is recognized as ASEAN’s first dedicated laboratory for evaluating biopharmaceutical product quality and ensuring regulatory compliance with international authorities.
-
GMP Production Facility: Utilizes microbial, mammalian cell, and single-use technology platforms to handle pilot-scale manufacturing, aseptic filling, and process validation for clinical research-grade products.
By anchoring these three pillars under one ecosystem, the facility targets one of the global life science industry’s steepest hurdles: the transition from initial discovery to commercial readiness. The integrated pipeline allows international partners, universities, and private biotech firms to cut development costs and accelerate their time-to-market.
The facility’s leadership team, scientists, and technical experts will be presenting these capabilities at the Pharma Lab Zone during the CPHI SouthEast Asia 2026 exhibition. The event will take place from July 8–10, 2026, at the Queen Sirikit National Convention Center (QSNCC) in Bangkok, where stakeholders will gather to discuss collaborations in vaccines, biologics, and advanced therapeutics.
Leave a Reply